We therefore aimed to perform a thorough, comprehensive IHC-based ARID1A protein expression analysis in a large cohort of urothelial bladder carcinomas including carcinoma in situ (CIS) cases. The gene discussed is ARID1A; the disease is in situ carcinoma.